VISEN Pharmaceuticals (HKSE:02561) General and Admin. Expense: HK$99.73 Mil (TTM As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

HKSE:02561 VISEN Pharmaceuticals HKSE:02561
7 GF Score
Price HK$19.98
! 5 Warning Signs
View Full Analysis

What is VISEN Pharmaceuticals General and Admin. Expense?

VISEN Pharmaceuticals HKSE:02561 7 General and Admin. Expense is HK$99.73 Mil as of Jun. 2026. GuruFocus rates HKSE:02561 with a GF Score™ of 7/100. The stock has 5 warning signs investors should review.

General and Admin. Expense is the aggregate total of general managing and administering expenses for the company. VISEN Pharmaceuticals's General and Admin. Expense for the six months ended in Jun. 2026 was HK$38.87 Mil. Its General and Admin. Expense for the trailing twelve months (TTM) ended in Jun. 2026 was HK$99.73 Mil.

VISEN Pharmaceuticals General and Admin. Expense Related Terms

VISEN Pharmaceuticals General and Admin. Expense Historical Data

* Premium members only.

The historical data trend for VISEN Pharmaceuticals's General and Admin. Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

VISEN Pharmaceuticals General and Admin. Expense Chart

VISEN Pharmaceuticals Annual Data
Trend Dec22 Dec23 Dec24 Dec25
General and Admin. Expense
46.36 87.44 92.28 127.20

VISEN Pharmaceuticals Semi-Annual Data
Dec22 Dec23 Jun24 Dec24 Jun25 Dec25 Jun26
General and Admin. Expense Get a 7-Day Free Trial 46.98 45.69 65.63 60.87 38.87
HKSE:02561
7GF Score
VISEN Pharmaceuticals HKSE:02561
General and Admin. Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

VISEN Pharmaceuticals General and Admin. Expense Calculation

General and Admin. Expense is the aggregate total of general managing and administering expenses for the company.

General and Admin. Expense for the trailing twelve months (TTM) ended in Jun. 2026 adds up the semi-annually data reported by the company within the most recent 12 months, which was HK$99.73 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a General and Admin. Expense of HK$99.73 Mil mean?
VISEN Pharmaceuticals (HKSE:02561) has a General and Admin. Expense of HK$99.73 Mil as of Jun. 2026. General and Admin. Expense is the aggregate total of general managing and administering expenses for the company. View historical data on VISEN Pharmaceuticals and its competitors.
Is VISEN Pharmaceuticals' General and Admin. Expense too high?
VISEN Pharmaceuticals' current General and Admin. Expense is HK$99.73 Mil. Overall, VISEN Pharmaceuticals has a GF Score™ of 7/100, reflecting its overall financial health beyond just this single metric.
How does VISEN Pharmaceuticals' General and Admin. Expense compare to ZTS?
VISEN Pharmaceuticals' General and Admin. Expense of HK$99.73 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good General and Admin. Expense for a Drug Manufacturers company?
A good General and Admin. Expense depends on the Drug Manufacturers industry context. However, General and Admin. Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high General and Admin. Expense mean?
A high General and Admin. Expense can signal that a stock is expensive relative to its fundamentals. General and Admin. Expense is the aggregate total of general managing and administering expenses for the company. View historical data on VISEN Pharmaceuticals and its competitors. VISEN Pharmaceuticals's current General and Admin. Expense is HK$99.73 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is VISEN Pharmaceuticals stock overvalued right now?
VISEN Pharmaceuticals (HKSE:02561) has a current General and Admin. Expense of HK$99.73 Mil. The current General and Admin. Expense is HK$99.73 Mil. VISEN Pharmaceuticals' overall GF Score™ is 7/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is General and Admin. Expense calculated?
General and Admin. Expense is calculated from a company's financial statements. For VISEN Pharmaceuticals (HKSE:02561), the current General and Admin. Expense is HK$99.73 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

VISEN Pharmaceuticals Business Description

Address 69 Jiuzhang Road, Suite 3-108, Floor 3, Building B, Hengtai Lixiang Chuangxin Tower, Suzhou, CHN
VISEN Pharmaceuticals is a late-stage, near-commercialization biopharmaceutical company focused on providing treatments in selected endocrinology diseases in China. It has one Core Product and two other pipeline drug candidates. Its Core Product, lonapegsomatropin, is a once-weekly long-acting growth hormone replacement therapy for the treatment of pediatric growth hormone deficiency (PGHD), a common short stature in patients aged under 18 caused by insufficient growth hormone. TransCon CNP (navepegritide), one of its key drug candidates, is a long-acting prodrug of c-type natriuretic peptide for the treatment of achondroplasia (ACH), a short-limbed dwarfism that results in severe skeletal complications and comorbidities.
7GF Score

Get the complete analysis for HKSE:02561

General and Admin. Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

HK$19.98
Price